Skip to main content
Log in

Long-term platinum excretion in patients treated with cisplatin

  • Short Communication
  • Cisplatin, Pharmacokinetics, Urinary Platinum
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The purpose of this study was to determine long-term renal platinum excretion after chemotherapy with cisplatin. We examined urinary platinum concentrations in 23 men at 150–3022 days after anticancer treatment for testicular neoplasm. Spot urine samples were analyzed by voltammetry. This new, subtle method with a detection limit of 2 pg platinum allows determination of even the natural background level. Urinary platinum concentrations in our patients ranged between 0.74 and 77.24 μg/g creatinine, depending on the total delivered dose and follow-up period. Regression analysis of the data showed two phases of long-term renal platinum excretion, one occurring at between 150 and 900 days of follow-up and the other with an onset at 900 days after cisplatin administration (r 1 2=0.82,r 2 2=0.88). Two biological half-lives of 160 and 720 days were calculated. Our results show that urinary platinum concentrations determined at 8 years after cisplatin therapy are 40 times higher than the background level (up to 0.02 μg/g creatinine). Our findings on the long-term pharmacolinetics of this anticancer agent may facilitate further studies on sites of platinum storage in the human body as well as clinical studies on the late adverse effects of cisplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Donohue JP (1977)cis-Diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293

    Google Scholar 

  2. Bosl G (1991/1992) Germ cell tumors. In: Wittes RE (ed) Manual of oncologic therapeutics. Lippincott, Philadelphia, p 189

    Google Scholar 

  3. Hölzel D, Altwein JE (1988) Hodentumoren — Ist der Rückgang der Mortalität in der Bundersrepublik Deutschland zu langsam erfolgt? Dtsch Ärzteblatt B 88: 2694–2700

    Google Scholar 

  4. Krakoff IJ (1979) Nephrotoxicity of cis-dichloroplatinum(II). Cancer Treat Rep 63: 1523

    Google Scholar 

  5. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozeneweig M, Young RC, Muggia FM (1979) Toxic effects ofcis-dichlorodiammine platinum (II) in man. Cancer Treat Rep 63: 1527

    Google Scholar 

  6. Fillastre JP, Raguenez-Viotte G (1989) Cisplatin nephrotoxicity. Toxicol Lett 46: 163

    Google Scholar 

  7. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938

    Google Scholar 

  8. Groth S, Nielsen H, Sorensen JB (1986) Acute and long-term nephrotoxicity of cisplatinum in man. Cancer Chemother Pharmacol 17: 191–196

    Google Scholar 

  9. Schwabe R, Herrmann R, Mathew M, Graf KJ, Sander T, Cordes M, Nagel R, Weissbach L, Huhn D (1992) Langfristige Toxizität der Polychemotherapie bei kurativ behandeltem Hodenkarzinom. Dtsch Med Wochenschr 117: 121–126

    Google Scholar 

  10. Roth BJ, Greist A, Kubilis PS, Williams LD, Einhorn LH (1988) Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol 6: 1239–1247

    Google Scholar 

  11. Greene MH (1992) Is cisplatin a human carcinogen? J Natl Cancer Inst 84: 306–312

    Google Scholar 

  12. International Ageney for Research on Cancer (1987) Overall evaluations of carcinogenity: an updating of IARC Monograph volumes 1 to 42. IARC Monogr [Suppl 7]: 170–171

    Google Scholar 

  13. Ensslin A, Pethran A, Schierl R, Fruhmann G (1994) Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Environ Health 65: 339

    Google Scholar 

  14. Messerschmidt J, Alt F, Tölg G, Angerer J, Schaller KH (1992) Adsorptive voltammetric procedure for the determination of platinum baseline levels in human body fluids. Fresenius Z Anal Chem 343: 391

    Google Scholar 

  15. Vaughan GT, Florence TM (1992) Platinum in the human diet, blood, hair and excreta. Sci Tot Environ 111: 47

    Google Scholar 

  16. Schierl R, Ensslin AS, Fruhmann G (1994) Führt der Straßenverkehr zu erhöhten Platinkonzentrationen im Urin von beruflich Exponierten? Verh Dtsch Ges Arbeitsmed 33: 291–294

    Google Scholar 

  17. Preusser P, Achterrath W, Niederle N, Seeber S (1985) Cisplatin. Arzneimitteltherapie 3: 50

    Google Scholar 

  18. Harland S, Newell D, Siddik Z, Chadwick R, Chadwick R, Calvert H, Harrap KR (1984) Pharmacokinetics ofcis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44: 1693

    Google Scholar 

  19. Gormeley P, Bull J, LeRoy A, Cysyk R (1979) Kinetics ofcis-dichlorodiammineplatinum. Clin Pharmacol Ther 25: 351

    Google Scholar 

  20. Ehninger G, Haag C, Wilms K (1984) Die Pharmakokinetik voncis-Diaminodichloroplatin. Tumor Diagn Ther 5: 147

    Google Scholar 

  21. Shani J, Bertram J, Russell C, Dahalan R, Chen CP, Parti R, ahmadi J, Kempf RA, Kawada TK, Muggia FM, Wolf W (1989) Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans. Cancer Res 49: 1877

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schierl, R., Rohrer, B. & Hohnloser, J. Long-term platinum excretion in patients treated with cisplatin. Cancer Chemother. Pharmacol. 36, 75–78 (1995). https://doi.org/10.1007/BF00685736

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685736

Key words

Navigation